Senvion S.A.

  • WKN: A2AFKW
  • ISIN: LU1377527517
  • Land: Luxemburg

Nachricht vom 20.03.2017 | 22:13

Senvion S.A.: 23_Interim Reporting

DGAP-News: Senvion S.A. / Key word(s): Share Buyback

20.03.2017 / 22:13
The issuer is solely responsible for the content of this announcement.


Senvion S.A.

WKN: A2AFKW ISIN: LU1377527517 Country: Grand Duchy of Luxembourg

Senvion S.A.: Release of capital market information

Senvion S.A. / Disclosure according to Art. 2 para. 3 of the Regulation (EU) no. 2016/1052 Share buyback - 23. Interim Reporting

Dissemination of a Post-admission Duties announcement, transmitted by DGAP - a service of EQS Group AG.

In the time period from March 13, 2017 until and including March 17, 2017, a number of 14,740 shares were bought back within the framework of the share buy-back program of Senvion S.A., whose start was disclosed by Senvion S.A. pursuant to Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 on August 25, 2016.

Day of purchase Aggregated volume in shares Weighted average price
13 March 2017 3,000 11.5049
14 March 2017 3,000 11.4022
15 March 2017 3,000 11.7586
16 March 2017 3,000 12.0047
17 March 2017 2,740 12.1467
 


The transactions in a detailed form are published on the website of Senvion S.A. under www.senvion.com under sub-category "investors".

The total volume of shares which have been bought back within the framework of the share buy-back amounts to 783,100 shares.

The purchase of the shares of Senvion S.A. is carried out by a credit institution that has been commissioned by Senvion S.A.; the shares are repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (Xetra).

Luxembourg, March 20, 2017
Senvion S.A.

The Managing Board

Contact:
Dhaval Vakil
Phone: +44 20 7034 7992
Mobile: +44 7788 390 185
Email: dhaval.vakil@senvion.com


 


20.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

News im Fokus

Erfolgreicher Start in das neue Geschäftsjahr für Continental

28. April 2017, 08:29

Aktueller Webcast

Scout24 AG

Q1 Results 2017

10. Mai 2017

Aktuelle Research-Studie

Nemetschek SE

Original-Research: Nemetschek SE (von Montega AG): Kaufen

28. April 2017